Search results for: HIV1-RT antibody, Monoclonal Antibodies, Host Mouse, Isotype IgG1
#30439343 // Save this To Up
Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.Antibody (Ab)-dependent enhancement can exacerbate dengue virus (DENV) infection due to cross-reactive Abs from an initial DENV infection, facilitating replication of a second DENV. Zika virus (ZIKV) emerged in DENV-endemic areas, raising questions about whether existing immunity could affect these related flaviviruses. We show that mice born with circulating maternal Abs against ZIKV develop severe disease upon DENV infection. Compared with pups of naive mothers, those born to ZIKV-immune mice lacking type I interferon receptor in myeloid cells (LysMCreIfnar1) exhibit heightened disease and viremia upon DENV infection. Passive transfer of IgG isolated from mice born to ZIKV-immune mothers resulted in increased viremia in naive recipient mice. Treatment with Abs blocking inflammatory cytokine tumor necrosis factor linked to DENV disease or Abs blocking DENV entry improved survival of DENV-infected mice born to ZIKV-immune mothers. Thus, the maternal Ab response to ZIKV infection or vaccination might predispose to severe dengue disease in infants.
2678 related Products with: Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.Goat Anti-Human ALDH1A1 ( Goat Anti-Human, Mouse BA Goat Anti-Rat IRAK3 (mous Cell Cycle Phospho-Specif Mouse Anti-Influenza A Vi Rabbit Anti-Human Inhibin Goat Anti-Human, Rat CCKB Inflammation (Human) Anti Goat Anti-Human, Mouse, R Goat Anti- GPR120, (inter Goat Anti-Human Myosin IX Goat Anti-Human ANKK1, (i
#30179634 // Save this To Up
Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.Influenza represents a global public health threat. Currently available influenza vaccines are effective against strain-matched influenza A and B viruses but do not protect against novel pandemic viruses. Vaccine candidates that target conserved B or T cell epitopes of influenza viruses could circumvent this shortcoming. The conserved extracellular domain of matrix protein 2 (M2e) of influenza A is an example of such a broadly protective vaccine candidate. Protection by M2e-based vaccine candidates largely depends on M2e-specific IgG antibodies. Here we show that the M2e-specific IgG2a monoclonal antibody 65 (MAb 65) can reduce influenza A/Udorn/72 (H3N2) and A/Hong Kong/68 (H3N2) virus plaque formation. This effect was not observed with other influenza A virus strains tested. We further show that passive transfer of MAb 65 to mice can reduce viral loads in the upper and lower airways, which results in reduced transmission of A/Udorn/72 and A/Hong Kong/68 viruses to cohoused, unimmunized contact mice. Virus restriction by passively transferred Mab 65 was significantly less pronounced in Fcgr1Fcgr3 mutant mice compared with wild type controls, suggesting that in vivo protection provided by MAb 65 depends on Fcγ receptor-mediated antibody effector mechanisms. We conclude that M2e-based antibody immune therapy has the potential to diminish influenza A virus replication in the immunized host as well as in exposed naïve contacts.
2145 related Products with: Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.Anti-Infectious Pancreati Anti-Infectious Pancreati Anti-Infectious Pancreati MOUSE ANTI CANINE DISTEMP Anti-Infectious Pancreati HA (Influenza A Virus Hem Avian Influenza virus H5N Measles Virus nucleoprote Mouse Anti-Influenza B Vi Mouse Anti-Insulin(1G11) Mouse Anti-Influenza B Vi Mouse Anti-Insulin(1G11)
#29866909 // Save this To Up
Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection.Enterotoxigenic (ETEC) causes diarrheal illness in infants in the developing world and travelers to countries where the disease is endemic, including military personnel. ETEC infection of the host involves colonization of the small intestinal epithelium and toxin secretion, leading to watery diarrhea. There is currently no vaccine licensed to prevent ETEC infection. CFA/I is one of the most common colonization factor antigens (CFAs). The CFA/I adhesin subunit, CfaE, is required for ETEC adhesion to host intestinal cells. Human antibodies against CfaE have the potential to block colonization of ETEC and serve as an immunoprophylactic against ETEC-related diarrhea. Mice transgenic for human immunoglobulin genes were immunized with CfaE to generate a panel of human monoclonal IgG1 antibodies (HuMAbs). The most potent IgG1 antibodies identified in the functional assays were selected and isotype switched to secretory IgA (sIgA) and tested in animal colonization assays via oral administration. Over 300 unique anti-CfaE IgG1 HuMAbs were identified. The lead IgG1 anti-CfaE HuMAbs completely inhibited hemagglutination and blocked adhesion of ETEC to Caco-2 cells. Epitope mapping studies revealed that HuMAbs recognized epitopes in the N-terminal domain of CfaE near the putative receptor binding site. Oral administration of anti-CfaE antibodies in either IgG or sIgA isotypes inhibited intestinal colonization in mice challenged with ETEC. A 2- to 4-log decrease in CFU was observed in comparison to mice challenged with irrelevant isotype controls. We identified fully human monoclonal antibodies against the CfaE adhesion domain that can be potentially employed as an immunoprophylactic to prevent ETEC-related diarrhea.
1482 related Products with: Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection.Hsp90 total Monoclonals A Aha1, 4H9-D7 Monoclonals E. coli antibody, Monoclo Goat Anti-Escherichia col Proteins and Antibodies H Proteins and Antibodies H Human Growth Hormone anti E. coli antibody, Monoclo MOUSE ANTI HUMAN CD15, Pr Human Serum Albumin antib Goat Anti-Human Androgen Anti Human AGO3, Monoclon
#29859099 // Save this To Up
Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.Proteolytic impairment of the Fc effector functions of therapeutic monoclonal antibodies (mAbs) can compromise their antitumor efficacy in the tumor microenvironment and may represent an unappreciated mechanism of host immune evasion. Pertuzumab is a human epidermal growth factor receptor 2 (HER2)-targeting antibody and has been widely used in the clinic in combination with trastuzumab for treatment of HER2-overexpressing breast cancer. Pertuzumab susceptibility to proteolytic hinge cleavage and its impact on the drug's efficacy has not been previously studied.
2475 related Products with: Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.MarkerGeneTM in vivo lacZ Resorufin Oleate, Fluorog Cell Meter™ Fluorimetri EnzyChrom™ Kinase Assay C Peptide ELISA Kit, Rat EpiQuik MBD2 Binding Acti Mouse Anti-Lipoprotein Li ELISA kit CLGI,Collagenas MarkerGeneTMFluorescent A EpiQuik Histone Methyltra MarkerGeneTM Fluorescent Frozen colorectal adenoca
#29740451 // Save this To Up
Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors.Influenza virus infection is a significant global health threat. Because of the lack of cross-protective universal vaccines, short time window during which antivirals are effective and drug resistance, new therapeutic anti-influenza strategies are required. Broadly, cross-protective antibodies that target conserved sites in the hemagglutinin (HA) stem region have been proposed as therapeutic agents. FI6 is the first proven such monoclonal antibody to bind to H1-H16 and is protective in mice and ferrets. Multiple studies have shown that Fc-dependent mechanisms are essential for FI6 efficacy. Here, we show that therapeutic administration of FI6 either intravenously or by aerosol to pigs did not reduce viral load in nasal swabs or broncho-alveolar lavage, but aerosol delivery of FI6 reduced gross pathology significantly. We demonstrate that pig Fc receptors do not bind human IgG1 and that FI6 did not mediate antibody-dependent cytotoxicity (ADCC) with pig PBMC, confirming that ADCC is an important mechanism of protection by anti-stem antibodies . Enhanced respiratory disease, which has been associated with pigs with cross-reactive non-neutralizing anti-HA antibodies, did not occur after FI6 administration. Our results also show that neutralizing antibody responses are not a robust correlate of protection for the control of influenza infection and pathology in a natural host model.
2023 related Products with: Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors.Human Serum Albumin antib Mouse anti Human IgM anti Human Growth Hormone anti Mouse anti-human type II PIG3 antibody Source Rabb SYK & FCGR1A Protein Prot anti CD66e IgG1 monoclona Human Growth Hormone anti Mouse anti Human IgG anti Mouse anti-human type II PIGR antibody Source Rabb MOUSE ANTI HUMAN CD19 RPE
#29643191 // Save this To Up
CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.Anti-CD83 Ab capable of Ab-dependent cellular cytotoxicity can deplete activated CD83 human dendritic cells, thereby inhibiting CD4 T cell-mediated acute graft-versus-host disease. As CD83 is also expressed on the surface of activated B lymphocytes, we hypothesized that anti-CD83 would also inhibit B cell responses to stimulation. We found that anti-CD83 inhibited total IgM and IgG production in vitro by allostimulated human PBMC. Also, Ag-specific Ab responses to immunization of SCID mice xenografted with human PBMC were inhibited by anti-CD83 treatment. This inhibition occurred without depletion of all human B cells because anti-CD83 lysed activated CD83 B cells by Ab-dependent cellular cytotoxicity and spared resting (CD83) B cells. In cultured human PBMC, anti-CD83 inhibited tetanus toxoid-stimulated B cell proliferation and concomitant dendritic cell-mediated CD4 T cell proliferation and expression of IFN-γ and IL-17A, with minimal losses of B cells (<20%). In contrast, the anti-CD20 mAb rituximab depleted >80% of B cells but had no effect on CD4 T cell proliferation and cytokine expression. By virtue of the ability of anti-CD83 to selectively deplete activated, but not resting, B cells and dendritic cells, with the latter reducing CD4 T cell responses, anti-CD83 may be clinically useful in autoimmunity and transplantation. Advantages might include inhibited expansion of autoantigen- or alloantigen-specific B cells and CD4 T cells, thus preventing further production of pathogenic Abs and inflammatory cytokines while preserving protective memory and regulatory cells.
1618 related Products with: CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.Human Antithrombin III to Human Vitronectin Total A Cell Meter™ Live Cell C Total Human uPA Antigen A Cell Meter™ Live Cell C Cell Meter™ Live Cell C Astra Blue 6GLL, Stain fo CellQuanti-Blue™ Cell V Cell Meter™ Live Cell C Cell Meter™ Fluorimetri Human Plasminogen Total A Cell Meter™ Live Cell C
#29386065 // Save this To Up
Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.Accumulating evidence indicates that Tau pathology can spread from neuron to neuron by intake and coaggregation of the hyperphosphorylated Tau (p-Tau) seeds with the host neuron protein. Thus, clearance of Tau seeds by immunization with Tau antibodies could provide a potential therapeutic opportunity to block the spread of the pathology in Alzheimer's disease (AD) and other tauopathies. We report prevention of the seeding and spread of tau pathology with mouse monoclonal antibody 43D against the N-terminal projection domain of Tau (Tau 6-18) in triple-transgenic AD (3 × Tg-AD) mice.
1874 related Products with: Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.Lung adenocarcinoma tissu Multiple organ tumor and Colorectal carcinoma and Rectum adenocarcinoma tis Brain tumor and adjacent Breast tumor survey tissu Ovary adenocarcinoma tiss Endometrium cancer tissue Stomach adenocarcinoma ti Liver cancer tissue array Ovary cancer tissue array Mid advanced stage uterin
#29325217 // Save this To Up
Neutrophil infiltration to the brain is platelet-dependent, and is reversed by blockade of platelet GPIbα.Neutrophils are key components of the innate immune response, providing host defence against infection and being recruited to non-microbial injury sites. Platelets act as a trigger for neutrophil extravasation to inflammatory sites but mechanisms and tissue-specific aspects of these interactions are currently unclear. Here, we use bacterial endotoxin in mice to trigger an innate inflammatory response in different tissues and measure neutrophil invasion with or without platelet reduction. We show that platelets are essential for neutrophil infiltration to the brain, peritoneum and skin. Neutrophil numbers do not rise above basal levels in the peritoneum and skin and are decreased (~60%) in the brain when platelet numbers are reduced. In contrast neutrophil infiltration in the lung is unaffected by platelet reduction, up-regulation of CXCL-1 (2·4-fold) and CCL5 (1·4-fold) acting as a compensatory mechanism in platelet-reduced mice during lung inflammation. In brain inflammation targeting platelet receptor GPIbα results in a significant decrease (44%) in platelet-mediated neutrophil invasion, while maintaining platelet numbers in the circulation. These results suggest that therapeutic blockade of platelet GPIbα could limit the harmful effects of excessive inflammation while minimizing haemorrhagic complications of platelet reduction in the brain. The data also demonstrate the ability to target damaging brain inflammation in stroke and related disorders without compromising lung immunity and hence risk of pneumonia, a major complication post stroke. In summary, our data reveal an important role for platelets in neutrophil infiltration to various tissues, including the brain, and so implicate platelets as a key, targetable component of cerebrovascular inflammatory disease or injury.
1947 related Products with: Neutrophil infiltration to the brain is platelet-dependent, and is reversed by blockade of platelet GPIbα.Clostridum difficile toxi Rabbit Anti-IEX1 Differen Rabbit Anti-IEX1 Differen Rabbit Anti-Neutrophil El Rabbit Anti-Neutrophil El Clostridum difficile toxi Rabbit Anti-IEX1 Differen Rabbit Anti-IEX1 Differen Rabbit Anti-Neutrophil El Clostridum difficile toxi 1,6-Anhydro-3,4-O-isoprop Cholera toxin antibody, M
#29248585 // Save this To Up
Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.Broadly reactive human monoclonal antibodies against the HA stem of influenza A virus are being developed as therapeutic agents as well as to understand the epitopes that are essential for a universal influenza virus vaccine.
1287 related Products with: Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.Hsp90 total Monoclonals A Rat Anti-Human CD77 (bloo VEGFR-2 (Human, monoclona Monoclonal Antibodies to Mouse anti human IL-22BP MOUSE ANTI HUMAN CD173 - Goat Anti-Human NAT10 hAL Goat Anti-Human Hamartin Goat Anti-Human E2-230K U Human Serum Albumin antib Sheep Anti-Human IFN-beta Endoglin (Human, monoclon
#28935938 // Save this To Up
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.The impact of broad-spectrum antibiotics on antimicrobial resistance and disruption of the beneficial microbiome compels the urgent investigation of bacteria-specific approaches such as antibody-based strategies. Among these, DNA-delivered monoclonal antibodies (DMAbs), produced by muscle cells in vivo, potentially allow the prevention or treatment of bacterial infections circumventing some of the hurdles of protein IgG delivery. Here, we optimize DNA-delivered monoclonal antibodies consisting of two potent human IgG clones, including a non-natural bispecific IgG1 candidate, targeting Pseudomonas aeruginosa. The DNA-delivered monoclonal antibodies exhibit indistinguishable potency compared to bioprocessed IgG and protect against lethal pneumonia in mice. The DNA-delivered monoclonal antibodies decrease bacterial colonization of organs and exhibit enhanced adjunctive activity in combination with antibiotics. These studies support DNA-delivered monoclonal antibodies delivery as a potential strategy to augment the host immune response to prevent serious bacterial infections, and represent a significant advancement toward broader practical delivery of monoclonal antibody immunotherapeutics for additional infectious pathogens.DNA-delivered monoclonal antibodies (DMAbs) can be produced by muscle cells in vivo, potentially allowing prevention or treatment of infectious diseases. Here, the authors show that two DMAbs targeting Pseudomonas aeruginosa proteins confer protection against lethal pneumonia in mice.
2363 related Products with: An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.Mouse Anti P.aeruginosa s Mouse Anti P.aeruginosa s Mouse Anti P. aeruginosa Chlamydia pneumoniae anti CRC3 CD3 (bispecific) Cl HIV1 integrase antibody, Clostridum difficile toxi Mac3 antibody (FITC), Con Rabbit Anti-NOS-2 iNOS Po Mouse Anti-Insulin(1D4 ) LAMA5 & LAMC1 Protein Pro Rabbit Anti-Insulin Polyc
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia